Breakthrough Status

Awarded by the FDA to allow further research into psilocybin

Revolutionary Treatment

For tobacco and alcohol addiction, depression and anxiety

Emerging Landscape

Psilocybin is one of the most effective psychedelics for the treatment of conditions such as treatment-resistant depression, anxiety, PTSD and depression.

These natural benefits, known for years to traditional societies, are only now are being researched after decades of stigmatization and inaccurate scaremongering.

The world’s leading academic institutions are compiling a growing amount of research into the benefits of psilocybin. Universities such as Imperial College London, the NYU Grossman School of Medicine and Johns Hopkins University, and medical research bodies including the Heffter Research Institute, the Beckley Foundation and MAPS have all contributed to this.

A few examples of research undertaken by these institutions


Mental Health


Global population with mental health/neurological disorders


People with inadequate first-line treatment options


Of people with serious substance abuse with inadequate treatment


Current global market for DPS treatment


Projected global market for mental health/neurological disorders in 2025

1 in 11

People will suffer from PTSD at some point in their lives
"Psychedelic events are going mainstream, where the much-maligned mushroom industry focuses on mental health"
"Recent studies are finding that drugs such as LSD and psilocybin can help to alleviate depression, anxiety and addiction"